Lack of Compliance with EMHS Redistribution Guidelines in Ugandan Health Facilities

By Staff Writer

March 10, 2023

Introduction

In public health, efficient management of Essential Medicines and Health Supplies (EMHS) is crucial. In Uganda, EMHS redistribution is a vital process that ensures healthcare facilities are equipped to serve their communities effectively.  Execution of the EMHS redistribution guidelines was lacking in public health facilities in Uganda. Just one third (33%) of the health facilities conformed with the EMHS redistribution guidelines.

Understanding EMHS Redistribution

EMHS redistribution involves transferring unused, non-expired health commodities from overstocked facilities to those in dire need. This system is particularly important in Uganda, where disparities in healthcare provision are common. By redistributing resources, the country can better manage its limited supplies, prevent wastage, and ensure a more equitable distribution of medical essentials.

The Current State of EMHS in Uganda

Despite the government’s efforts, the healthcare sector often encounters stock-outs and excesses in EMHS. With a budget that falls short of the Abuja Declaration’s recommendations, the sector struggles to meet the demands of its populace. Redistribution of EMHS is a strategy to mitigate these challenges, yet compliance with guidelines remains low, at just 33.3%.

Challenges in Redistribution

A primary obstacle in the redistribution process is the lack of guideline dissemination, resulting in significant knowledge gaps among healthcare staff. This study found that respondents who reported that the guidelines were never shared with staff in other departments were 88% less likely to comply. Failure to share guidelines further led to staff knowledge gaps, as over half (54.5%) of the staff did not know about the guidelines. Furthermore, unclear financial responsibilities and bureaucratic procedures further hinder the efficient movement of supplies. These systemic issues contribute to stock discrepancies and ultimately affect patient care.

Strategies for Improvement

To address these challenges, it is essential to ensure that guidelines are accessible and understood by all relevant staff. Financial transparency and streamlined procedures can alleviate some of the bottlenecks in the system. Furthermore, consistent delivery schedules from the National Medical Stores can reduce the uncertainty that leads to stock hoarding. To improve compliance with redistribution:

  1. Allocation of funds for transporting medicines should be considered by the district.
  2. Health facility managers should raise awareness among staff working in stores concerning the redistribution process.
  3. The District Health Officer (DHO) should make it a priority to routinely monitor health facilities particularly to avoid the issue of medicine stock-outs and overstocking.

Conclusion

Enhancing EMHS redistribution requires a multifaceted approach, focusing on education, financial planning, and procedural efficiency. By tackling these issues, Uganda can move towards a more resilient and responsive healthcare system.

 

Reference url

Recent Posts

access to medicines
         

Quantifying EU Medicine Access Challenges

🔍 Are we creating a healthcare system that truly works for everyone?

Recent findings from EFPIA shed light on alarming inequities in access to medicines across Europe, showing that only 46% of approved drugs are available to patients this year. With significant delays affecting smaller markets and critical cancer treatments, this article explores the systemic barriers at play and innovative solutions proposed to ensure fair access.

Dive into the full article to uncover how we can collectively shape a more equitable healthcare landscape.

#SyenzaNews #healthcare #MarketAccess

UK Medicine Payment Rates
      

Revitalizing Innovation: The Impact of UK Medicine Payment Rates

💡 Are the UK’s medicine payment rates stifling innovation in life sciences?

Recent analysis reveals that the staggering 23.5% payment rate for pharmaceuticals is not just limiting NHS spending but also curtailing R&D investments, delaying new drug launches, and threatening workforce stability. If we can lower these rates to below 10%, we could unleash significant growth and restore the UK’s competitive edge in the global life sciences landscape.

Discover the critical insights and recommendations that could reshape the future of healthcare in the UK.

#SyenzaNews #healthcarepolicy #innovation

Blinatumomab benefit assessment
            

Blinatumomab Benefit Assessment for ALL and Health Economics

🚀 How does a groundbreaking therapy change the landscape of acute lymphoblastic leukemia treatment?

The recent benefit assessment of Blinatumomab by the German Federal Joint Committee reveals critical insights into its potential as a consolidation therapy for adults with Philadelphia chromosome-negative B-cell precursor ALL. With its orphan drug status promising automatic benefits, the article explores the implications of its high cost and economic impacts, shedding light on the balance needed between innovation and sustainability in healthcare.

Jump into the full analysis to understand how this could impact clinical practice and health economics.

#SyenzaNews #HealthEconomics #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.